ASRT
Assertio Holdings, Inc.
Price Chart
Latest Quote
$23.50
+0.00 (+0.00%)
Current Price
| Previous Close | $23.50 |
| Open | $23.48 |
| Day High | $23.50 |
| Day Low | $23.48 |
| Volume | 270,191 |
Stock Information
| Shares Outstanding | 6.46M |
| Total Debt | $40.31M |
| Cash Equivalents | $71.57M |
| Revenue | $102.16M |
| Net Income | $-35.69M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $151.86M |
| EPS (TTM) | $-5.55 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $120.61M |
| Sales | $102.16M |
| Income | $-35.69M |
| Book/sh | $11.73 |
| Cash/sh | $11.08 |
| Employees | 53 |
Financial Ratios
| Quick Ratio | 1.45 |
| Current Ratio | 1.82 |
| Debt/Eq | 53.30 |
Returns & Margins
| ROA | -5.71% |
| ROE | -38.76% |
| Gross Margin | 70.33% |
| Operating Margin | -185.95% |
| Profit Margin | -34.94% |
Ownership
| Insider Ownership | 1.97% |
| Institutional Ownership | 29.29% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.11 |
| PEG | 0.89 |
| P/S | 1.49 |
| P/B | 2.00 |
Analyst Data
| Recommendation | buy |
| Target Price | $24.43 |
Technical Indicators
| SMA20 | $23.45 |
| SMA50 | $21.25 |
| SMA200 | $14.51 |
| RSI | 71.43 |
| ATR | 0.0279 |
| Shares Float | 6.26M |
| Short Float | 5.25% |
| Short Ratio | 0.71 |
| Volatility | 0.53 |
Performance History
| Week | +0.17% |
| Month | +0.77% |
| Quarter | +88.00% |
| 6 Months | +106.14% |
| YTD | +157.11% |
| Year | +148.68% |
| 3 Years | -73.45% |
| 5 Years | -19.24% |
| 10 Years | -97.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $23.50 | 0 |
| 2026-06-15 | $23.50 | 271,800 |
| 2026-06-12 | $23.48 | 485,900 |
| 2026-06-11 | $23.47 | 297,800 |
| 2026-06-10 | $23.48 | 439,200 |
| 2026-06-09 | $23.46 | 547,000 |
| 2026-06-08 | $23.43 | 565,800 |
| 2026-06-05 | $23.44 | 517,200 |
| 2026-06-04 | $23.45 | 154,800 |
| 2026-06-03 | $23.47 | 126,800 |
| 2026-06-02 | $23.45 | 93,500 |
| 2026-06-01 | $23.43 | 184,800 |
| 2026-05-29 | $23.44 | 71,300 |
| 2026-05-28 | $23.44 | 110,500 |
| 2026-05-27 | $23.41 | 353,200 |
| 2026-05-26 | $23.46 | 233,300 |
| 2026-05-22 | $23.44 | 284,900 |
| 2026-05-21 | $23.37 | 281,800 |
| 2026-05-20 | $23.44 | 398,200 |
| 2026-05-19 | $23.41 | 528,500 |
| 2026-05-18 | $23.32 | 175,600 |
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
đ° Latest News
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
BioPharma Dive âĸ 2026-05-13T10:27:40Z
Assertio (ASRT) Moves 17.0% Higher: Will This Strength Last?
Zacks âĸ 2026-05-05T10:56:00Z
How The Assertio Holdings (ASRT) Story Is Shifting With The Garda Takeover And Valuation Anchor
Simply Wall St. âĸ 2026-05-05T07:12:03Z
Are Medical Stocks Lagging Assertio (ASRT) This Year?
Zacks âĸ 2026-04-30T13:40:02Z
How The Assertio Holdings (ASRT) Story Is Shifting With The Takeover And Reset Valuation
Simply Wall St. âĸ 2026-04-20T18:05:12Z
Does Assertio (ASRT) Have the Potential to Rally 115.05% as Wall Street Analysts Expect?
Zacks âĸ 2026-04-09T13:55:03Z
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-04-09T13:40:04Z
Assertio Holdings (ASRT) Issues 2026 Sales Guidance After Wider 2025 Losses Has The Bull Case Changed?
Simply Wall St. âĸ 2026-03-28T23:03:16Z
Assertio (ASRT) Surges 17.9%: Is This an Indication of Further Gains?
Zacks âĸ 2026-03-25T12:35:00Z
Wall Street Analysts Predict an 182.79% Upside in Assertio (ASRT): Here's What You Should Know
Zacks âĸ 2026-03-24T13:55:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $35,241,000 | $39,042,000 | $26,318,000 | $17,960,000 |
| Cost Of Revenue | $35,383,000 | $39,227,000 | $27,020,000 | $18,748,000 |
| Total Revenue | $118,713,000 | $124,961,000 | $152,069,000 | $156,234,000 |
| Operating Revenue | $118,713,000 | $122,861,000 | $151,884,000 | $157,524,000 |
| Expenses | ||||
| Interest Expense | $2,600,000 | $2,600,000 | $2,925,000 | $7,725,000 |
| Total Expenses | $135,936,000 | $143,744,000 | $136,028,000 | $98,142,000 |
| Other Income Expense | $-12,307,000 | $-2,928,000 | $-259,200,000 | $-18,965,000 |
| Other Non Operating Income Expenses | $180,000 | $2,765,000 | $377,000 | $-278,000 |
| Net Non Operating Interest Income Expense | $-410,000 | $182,000 | $-10,895,000 | $-7,961,000 |
| Total Other Finance Cost | $475,000 | $439,000 | $10,373,000 | $236,000 |
| Interest Expense Non Operating | $2,600,000 | $2,600,000 | $2,925,000 | $7,725,000 |
| Operating Expense | $100,553,000 | $104,517,000 | $109,008,000 | $79,394,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Net Interest Income | $-410,000 | $182,000 | $-10,895,000 | $-7,961,000 |
| Interest Income | $2,665,000 | $3,221,000 | $2,403,000 | - |
| Normalized Income | $-20,510,270 | $-17,083,530 | $-126,876,170 | $124,387,730 |
| Net Income From Continuing And Discontinued Operation | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Total Operating Income As Reported | $-21,536,000 | $-24,476,000 | $-243,536,000 | $-39,405,000 |
| Net Income Common Stockholders | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Net Income | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Net Income Including Noncontrolling Interests | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Net Income Continuous Operations | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Pretax Income | $-29,940,000 | $-21,529,000 | $-254,054,000 | $31,166,000 |
| Special Income Charges | $-12,487,000 | $-5,693,000 | $-259,577,000 | $-18,687,000 |
| Interest Income Non Operating | $2,665,000 | $3,221,000 | $2,403,000 | - |
| Operating Income | $-17,223,000 | $-18,783,000 | $16,041,000 | $58,092,000 |
| Depreciation Amortization Depletion Income Statement | $29,863,000 | $25,644,000 | $27,527,000 | $32,608,000 |
| Depreciation And Amortization In Income Statement | $29,863,000 | $25,644,000 | $27,527,000 | $32,608,000 |
| Amortization Of Intangibles Income Statement | $29,863,000 | $25,644,000 | $27,527,000 | $32,608,000 |
| Gross Profit | $83,330,000 | $85,734,000 | $125,049,000 | $137,486,000 |
| Average Dilution Earnings | - | - | $0 | $1,560,000 |
| Per Share | ||||
| Diluted EPS | $-4.74 | $-3.45 | $-70.05 | $30.45 |
| Basic EPS | $-4.74 | $-3.45 | $-70.05 | $34.95 |
| Other | ||||
| Tax Effect Of Unusual Items | $-2,622,270 | $-1,195,530 | $-54,511,170 | $-3,924,270 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $15,152,000 | $12,593,000 | $36,677,000 | $90,974,000 |
| Total Unusual Items | $-12,487,000 | $-5,693,000 | $-259,577,000 | $-18,687,000 |
| Total Unusual Items Excluding Goodwill | $-12,487,000 | $-5,693,000 | $-259,577,000 | $-18,687,000 |
| Reconciled Depreciation | $30,005,000 | $25,829,000 | $28,229,000 | $33,396,000 |
| EBITDA (Bullshit earnings) | $2,665,000 | $6,900,000 | $-222,900,000 | $72,287,000 |
| EBIT | $-27,340,000 | $-18,929,000 | $-251,129,000 | $38,891,000 |
| Diluted Average Shares | $6,403,000 | $6,351,400 | $4,735,400 | $3,644,600 |
| Basic Average Shares | $6,403,000 | $6,351,400 | $4,735,400 | $3,133,600 |
| Diluted NI Availto Com Stockholders | $-30,375,000 | $-21,581,000 | $-331,942,000 | $111,185,000 |
| Tax Provision | $435,000 | $52,000 | $77,888,000 | $-78,459,000 |
| Gain On Sale Of Business | $-8,174,000 | $0 | - | - |
| Impairment Of Capital Assets | $1,700,000 | $5,217,000 | $279,639,000 | $0 |
| Restructuring And Mergern Acquisition | $2,613,000 | $476,000 | $-20,062,000 | $18,687,000 |
| Amortization | $29,863,000 | $25,644,000 | $27,527,000 | $32,608,000 |
| Research And Development | $1,690,000 | $3,822,000 | $2,843,000 | $0 |
| Selling General And Administration | $69,000,000 | $75,051,000 | $78,638,000 | $46,786,000 |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $45,044,000 | $40,610,000 | $26,671,000 | $27,729,000 |
| Total Assets | $266,970,000 | $284,732,000 | $286,419,000 | $413,913,000 |
| Total Non Current Assets | $50,323,000 | $82,182,000 | $115,357,000 | $281,651,000 |
| Goodwill And Other Intangible Assets | $48,908,000 | $80,471,000 | $111,332,000 | $197,996,000 |
| Other Intangible Assets | $48,908,000 | $80,471,000 | $111,332,000 | $197,996,000 |
| Current Assets | $216,646,000 | $202,549,000 | $171,062,000 | $132,262,000 |
| Other Current Assets | $344,000 | $303,000 | $299,000 | $8,268,000 |
| Prepaid Assets | $8,667,000 | $9,764,000 | $11,973,000 | $8,268,000 |
| Inventory | $24,120,000 | $38,308,000 | $37,686,000 | $13,696,000 |
| Receivables | $120,110,000 | $54,120,000 | $47,663,000 | $45,357,000 |
| Accounts Receivable | $120,110,000 | $54,120,000 | $47,663,000 | $45,357,000 |
| Allowance For Doubtful Accounts Receivable | $-3,000,000 | $-1,200,000 | $-900,000 | $-900,000 |
| Gross Accounts Receivable | $123,110,000 | $55,320,000 | $48,563,000 | $46,257,000 |
| Cash Cash Equivalents And Short Term Investments | $63,405,000 | $100,054,000 | $73,441,000 | $64,941,000 |
| Cash And Cash Equivalents | $10,229,000 | $50,588,000 | $73,441,000 | $64,941,000 |
| Non Current Prepaid Assets | - | $1,000 | $1,289,000 | $1,607,000 |
| Other Non Current Assets | - | - | $697,000 | $965,000 |
| Non Current Deferred Assets | - | - | $0 | $80,202,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $80,202,000 |
| Debt | ||||
| Net Debt | $28,891,000 | - | - | $1,932,000 |
| Total Debt | $40,009,000 | $39,767,000 | $39,676,000 | $66,873,000 |
| Long Term Debt And Capital Lease Obligation | $40,009,000 | $39,767,000 | $39,676,000 | $66,403,000 |
| Long Term Debt | $39,120,000 | $38,645,000 | $38,206,000 | $66,403,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $470,000 |
| Current Debt | - | - | - | $470,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $173,018,000 | $163,651,000 | $148,416,000 | $188,188,000 |
| Total Non Current Liabilities Net Minority Interest | $45,505,000 | $48,963,000 | $54,973,000 | $92,872,000 |
| Other Non Current Liabilities | $3,074,000 | $5,479,000 | $9,224,000 | $22,200,000 |
| Derivative Product Liabilities | $4,000 | $168,000 | $308,000 | - |
| Non Current Deferred Liabilities | $2,418,000 | $3,549,000 | $5,765,000 | $4,269,000 |
| Non Current Deferred Taxes Liabilities | $2,418,000 | $2,337,000 | $4,553,000 | $4,269,000 |
| Current Liabilities | $127,513,000 | $114,688,000 | $93,443,000 | $95,316,000 |
| Other Current Liabilities | $4,851,000 | $4,801,000 | $3,654,000 | $27,248,000 |
| Payables And Accrued Expenses | $119,941,000 | $106,627,000 | $87,351,000 | $64,481,000 |
| Interest Payable | $867,000 | $867,000 | $867,000 | $1,593,000 |
| Payables | $9,014,000 | $14,736,000 | $13,439,000 | $5,991,000 |
| Accounts Payable | $9,014,000 | $14,736,000 | $13,439,000 | $5,991,000 |
| Total Tax Payable | - | - | $0 | $0 |
| Equity | ||||
| Common Stock Equity | $93,952,000 | $121,081,000 | $138,003,000 | $225,725,000 |
| Total Equity Gross Minority Interest | $93,952,000 | $121,081,000 | $138,003,000 | $225,725,000 |
| Stockholders Equity | $93,952,000 | $121,081,000 | $138,003,000 | $225,725,000 |
| Retained Earnings | $-703,499,000 | $-673,124,000 | $-651,543,000 | $-319,601,000 |
| Other | ||||
| Ordinary Shares Number | $6,421,899 | $6,369,132 | $6,311,234 | $3,221,322 |
| Share Issued | $6,421,899 | $6,369,132 | $6,311,234 | $3,221,322 |
| Tangible Book Value | $45,044,000 | $40,610,000 | $26,671,000 | $27,729,000 |
| Invested Capital | $133,072,000 | $159,726,000 | $176,209,000 | $292,598,000 |
| Working Capital | $89,133,000 | $87,861,000 | $77,619,000 | $36,946,000 |
| Capital Lease Obligations | $889,000 | $1,122,000 | $1,470,000 | $0 |
| Total Capitalization | $133,072,000 | $159,726,000 | $176,209,000 | $292,128,000 |
| Additional Paid In Capital | $797,450,000 | $794,204,000 | $789,537,000 | $545,321,000 |
| Capital Stock | $1,000 | $1,000 | $9,000 | $5,000 |
| Common Stock | $1,000 | $1,000 | $9,000 | $5,000 |
| Long Term Capital Lease Obligation | $889,000 | $1,122,000 | $1,470,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,721,000 | $3,260,000 | $2,438,000 | $3,117,000 |
| Current Accrued Expenses | $110,927,000 | $91,891,000 | $73,912,000 | $58,490,000 |
| Net PPE | $1,415,000 | $1,711,000 | $2,039,000 | $881,000 |
| Accumulated Depreciation | $-3,539,000 | $-3,397,000 | $-4,631,000 | $-3,933,000 |
| Gross PPE | $4,954,000 | $5,108,000 | $6,670,000 | $4,814,000 |
| Leases | $2,551,000 | $2,551,000 | $2,945,000 | $2,945,000 |
| Other Properties | $991,000 | $1,145,000 | $1,289,000 | $157,000 |
| Machinery Furniture Equipment | $1,412,000 | $1,412,000 | $1,908,000 | $1,712,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,896,000 | $17,884,000 | $24,910,000 | $9,594,000 |
| Work In Process | $6,051,000 | $4,900,000 | $2,239,000 | $2,735,000 |
| Raw Materials | $15,173,000 | $15,524,000 | $10,537,000 | $1,367,000 |
| Other Short Term Investments | $53,176,000 | $49,466,000 | $0 | - |
| Construction In Progress | - | $0 | $528,000 | $0 |
| Treasury Shares Number | - | - | $0 | - |
| Investments And Advances | - | - | - | $268,000 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-28,182,000 | $26,408,000 | $48,976,000 | $78,324,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-28,182,000 | $26,408,000 | $49,604,000 | $78,598,000 |
| Cash Flow From Continuing Operating Activities | $-28,182,000 | $26,408,000 | $49,604,000 | $78,598,000 |
| Operating Gains Losses | $8,174,000 | - | - | $-1,046,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-11,988,000 | $-48,911,000 | $3,097,000 | $-42,673,000 |
| Cash Flow From Continuing Investing Activities | $-11,988,000 | $-48,911,000 | $3,097,000 | $-42,673,000 |
| Capital Expenditure | - | - | $-628,000 | $-274,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-189,000 | $-350,000 | $-7,898,000 | $-838,000 |
| Financing Cash Flow | $-189,000 | $-350,000 | $-44,201,000 | $-7,794,000 |
| Cash Flow From Continuing Financing Activities | $-189,000 | $-350,000 | $-44,201,000 | $-7,794,000 |
| Net Common Stock Issuance | $-189,000 | $-350,000 | $-7,898,000 | $6,182,000 |
| Issuance Of Capital Stock | - | - | $0 | $7,020,000 |
| Net Other Financing Charges | - | - | $-25,803,000 | $-13,226,000 |
| Common Stock Issuance | - | - | $0 | $7,020,000 |
| Other | ||||
| Interest Paid Supplemental Data | $2,600,000 | $2,600,000 | $3,651,000 | $7,752,000 |
| End Cash Position | $10,229,000 | $50,588,000 | $73,441,000 | $64,941,000 |
| Beginning Cash Position | $50,588,000 | $73,441,000 | $64,941,000 | $36,810,000 |
| Changes In Cash | $-40,359,000 | $-22,853,000 | $8,500,000 | $28,131,000 |
| Common Stock Payments | $-189,000 | $-350,000 | $-7,898,000 | $-838,000 |
| Net Investment Purchase And Sale | $-3,814,000 | $-48,911,000 | $2,194,000 | $0 |
| Sale Of Investment | $115,383,000 | $49,694,000 | $2,194,000 | $0 |
| Purchase Of Investment | $-119,197,000 | $-98,605,000 | $0 | - |
| Net Business Purchase And Sale | $-8,174,000 | $0 | $1,531,000 | $-42,399,000 |
| Purchase Of Business | $-8,174,000 | $0 | $-419,000 | $-42,399,000 |
| Change In Working Capital | $-45,333,000 | $5,204,000 | $140,000 | $-13,014,000 |
| Change In Payables And Accrued Expense | $9,770,000 | $16,910,000 | $-42,387,000 | $-13,444,000 |
| Change In Accrued Expense | $23,062,000 | $18,166,000 | $-13,039,000 | $-3,331,000 |
| Change In Payable | $-13,292,000 | $-1,256,000 | $-29,348,000 | $-10,113,000 |
| Change In Account Payable | $-13,292,000 | $-1,256,000 | $-29,348,000 | $-10,113,000 |
| Change In Prepaid Assets | $1,209,000 | $4,334,000 | $-1,169,000 | $8,019,000 |
| Change In Inventory | $9,678,000 | $-9,583,000 | $-4,973,000 | $-6,593,000 |
| Change In Receivables | $-65,990,000 | $-6,457,000 | $48,669,000 | $-996,000 |
| Changes In Account Receivables | $-65,990,000 | $-6,457,000 | $48,669,000 | $-996,000 |
| Other Non Cash Items | $-317,000 | $-2,230,000 | $-15,109,000 | $19,243,000 |
| Stock Based Compensation | $3,454,000 | $5,009,000 | $9,158,000 | $7,504,000 |
| Provisionand Write Offof Assets | $4,510,000 | $8,960,000 | $3,288,000 | $3,265,000 |
| Asset Impairment Charge | $1,700,000 | $5,217,000 | $279,639,000 | $0 |
| Depreciation Amortization Depletion | $30,005,000 | $25,829,000 | $28,229,000 | $33,396,000 |
| Depreciation And Amortization | $30,005,000 | $25,829,000 | $28,229,000 | $33,396,000 |
| Depreciation | $30,005,000 | $25,829,000 | $28,229,000 | $33,396,000 |
| Gain Loss On Investment Securities | $8,174,000 | - | - | - |
| Net Income From Continuing Operations | $-30,375,000 | $-21,581,000 | $-331,942,000 | $109,625,000 |
| Repayment Of Debt | - | $0 | $-10,500,000 | $-70,750,000 |
| Income Tax Paid Supplemental Data | - | $1,594,000 | $4,031,000 | - |
| Net Issuance Payments Of Debt | - | $0 | $-10,500,000 | $-750,000 |
| Net Long Term Debt Issuance | - | $0 | $-10,500,000 | $-750,000 |
| Long Term Debt Payments | - | $0 | $-10,500,000 | $-70,750,000 |
| Sale Of Business | - | $0 | $1,950,000 | $0 |
| Net PPE Purchase And Sale | - | $0 | $-628,000 | $-274,000 |
| Purchase Of PPE | - | $0 | $-628,000 | $-274,000 |
| Change In Interest Payable | - | $0 | $-726,000 | $-95,000 |
| Deferred Tax | - | $0 | $76,201,000 | $-80,375,000 |
| Deferred Income Tax | - | $0 | $76,201,000 | $-80,375,000 |
| Issuance Of Debt | - | - | $0 | $70,000,000 |
| Long Term Debt Issuance | - | - | $0 | $70,000,000 |
| Proceeds From Stock Option Exercised | - | - | - | $34,000 |
| Change In Other Working Capital | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
| Gain Loss On Sale Of Business | - | - | - | - |
Fetched: 2026-06-15